The Lancet Respiratory Medicine in conversation with
Editors at The Lancet Respiratory Medicine, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.
A monthly audio companion to the journal, this podcast covers a broad range of topics, from long COIVD outcomes to tobacco control, the management of uncontrolled asthma to intensive care medicine, and more.
Podcasting since 2012 • 159 episodes
The Lancet Respiratory Medicine in conversation with
Latest Episodes
Marcus J Schultz and Prashant Nasa on defining and subphenotyping ARDS
Bianca Brandon is joined by Professor Marcus Schultz and Dr Prashant Nasa to discuss their recent Position Paper reporting insights from an international Delphi expert panel on defining and subphenotyping ARDS. The findings underscore the need ...
•
11:51
Hjalmar Bouma on sepsis in patients who are immunocompromised
Bianca Brandon, Senior Editor at The Lancet Respiratory Medicine, is joined by Professor Hjalmar Bouma to discuss a new review on sepsis in immunocompromised patients, exploring the diagnostic challenges, complexities of immune status,...
•
13:33
Simon Wolf on pulmonary embolism in children and adolescents in the US during 2016 and 2019
Deputy Editor of The Lancet Respiratory Medicine Ari Colosio discusses the critical findings of a new epidemiological study on pulmonary embolism in children and adolescents with Simon Wolf from the University Hospital of Zurich.&...
•
11:47
Sandeep Sahay and Franck Rahaghi on future treatment paradigms in pulmonary arterial hypertension
Dr Sandeep Sahay and Professor Franck Rahaghi discuss their Personal View on future treatment paradigms in pulmonary arterial hypertension.Read the full paper, Future treatment paradigms in pulmonary arterial hypertension: a personal...
•
14:53
Sergio Harari sul trattamento della linfangioleiomiomatosi (LAM) (in Italian)
Il Professor Sergio Harari commenta i risultati di un trial clinico di fase 2 volto a valutare l’attivita’ e la sicurezza del farmaco nintedanib come trattamento in pazienti affetti da linfangioleiomiomatosi (LAM).
•
10:40